Alzheimer’s disease (AD) is a complex neurodegenerative disease that leads to insidious deterioration of brain functions. Current treatments for AD that focus on inhibition of amyloid beta (Aβ) aggregation failed to show effectiveness in people with AD symptoms.
Strategies that synergistically exert neuroprotection and alleviation of oxidative stress could be a promising approach to correct the pathological brain microenvironment.
Now, a research team led by Dr. Yu Yin from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences has developed blood-brain-barrier-permeable nanoparticles for AD treatment based on selective mitophagy of microglia by restoration of mitochondrial function.
Nanosynth Group plc (LON:NNN) nano-technology business that originated in Nottingham from a partnership with Nottingham Trent University. Their core mission is to develop unique ways to produce and apply nanoparticles.